Search results
Showing 76 to 90 of 146 results for pneumonia
Comparator, Outcome) P: patients 18 years and under who have COVID-19 pneumonia I: treatment-dose LMWH C: standard prophylaxis with LMWH...
This quality standard covers managing intravenous (IV) fluid therapy safely and effectively for adults in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS66Show all sections
Sections for QS66
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
16 years and over who have been discharged after treatment for COVID-19 pneumonia I: extended (2 to 6 weeks) pharmacological VTE...
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
reduction in complications such as venous thromboembolism and hypostatic pneumonia. There could be benefits for motor and sensory...
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.
Comparator, Outcome) P: patients 16 years and over being treated for COVID-19 pneumonia in hospital or the communitywho have:• no...
How cost effective are fluoride varnish programmes and tooth-brushing schemes?
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
pre-cancer, and non dental clinical outcomes such as the prevalence of pneumonia and malnutrition in the elderly. Non-clinical outcomes...
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.
View recommendations for TA199Show all sections